Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists - PubMed (original) (raw)
Review
Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists
Rashmi Talwar et al. CNS Neurol Disord Drug Targets. 2011 Aug.
Abstract
Cannabinoids are antinociceptive in animal models of acute pain, tissue injury and nerve injury induced nociception and act via their cognate receptors, cannabinoid receptor 1 and 2. This review examines the underlying biology of the endocannabinoids and behavioural, neurophysiological, neuroanatomical evidence supporting the notion of pain modulation by these ligands with a focus on the current evidence encompassing the pharmacological characterization of CB1 agonists in this therapy. Separating the psychotropic effects of CB1 agonists from their therapeutic benefits is the major challenge facing researchers in the field today and with the discovery of peripherally acting agonists there seems to be a ray of hope emerging for the diverse potential therapeutic applications of this class of ligands.
Similar articles
- Cannabinoid mechanisms of pain suppression.
Walker JM, Hohmann AG. Walker JM, et al. Handb Exp Pharmacol. 2005;(168):509-54. doi: 10.1007/3-540-26573-2_17. Handb Exp Pharmacol. 2005. PMID: 16596786 Review. - Recent data on cannabinoids and their pharmacological implications in neuropathic pain.
Coman OA, Paunescu H, Coman L, Badarau A, Fulga I. Coman OA, et al. J Med Life. 2008 Oct-Dec;1(4):365-75. J Med Life. 2008. PMID: 20108515 Free PMC article. Review. - Pharmacological actions of cannabinoids.
Pertwee RG. Pertwee RG. Handb Exp Pharmacol. 2005;(168):1-51. doi: 10.1007/3-540-26573-2_1. Handb Exp Pharmacol. 2005. PMID: 16596770 Review. - Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
De Petrocellis L, Di Marzo V. De Petrocellis L, et al. J Neuroimmune Pharmacol. 2010 Mar;5(1):103-21. doi: 10.1007/s11481-009-9177-z. Epub 2009 Oct 22. J Neuroimmune Pharmacol. 2010. PMID: 19847654 Review. - [The cannabinoid system and pain: towards new drugs?].
Beltramo M. Beltramo M. J Soc Biol. 2009;203(1):99-106. doi: 10.1051/jbio:2009002. Epub 2009 Apr 10. J Soc Biol. 2009. PMID: 19358815 Review. French.
Cited by
- Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition.
Papa A, Pasquini S, Contri C, Gemma S, Campiani G, Butini S, Varani K, Vincenzi F. Papa A, et al. Cells. 2022 Jan 29;11(3):471. doi: 10.3390/cells11030471. Cells. 2022. PMID: 35159280 Free PMC article. Review. - Advice to People with Parkinson's in My Clinic: Cannabis.
de Freitas MET, Fox SH. de Freitas MET, et al. J Parkinsons Dis. 2024;14(4):873-881. doi: 10.3233/JPD-230358. J Parkinsons Dis. 2024. PMID: 38759024 Free PMC article. Review. - CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons.
McDowell TS, Wang ZY, Singh R, Bjorling D. McDowell TS, et al. Neurosci Lett. 2013 Sep 13;551:34-8. doi: 10.1016/j.neulet.2013.06.066. Epub 2013 Jul 12. Neurosci Lett. 2013. PMID: 23850608 Free PMC article. - Allele-specific differences in activity of a novel cannabinoid receptor 1 (CNR1) gene intronic enhancer in hypothalamus, dorsal root ganglia, and hippocampus.
Nicoll G, Davidson S, Shanley L, Hing B, Lear M, McGuffin P, Ross R, MacKenzie A. Nicoll G, et al. J Biol Chem. 2012 Apr 13;287(16):12828-34. doi: 10.1074/jbc.M111.336750. Epub 2012 Feb 23. J Biol Chem. 2012. PMID: 22362764 Free PMC article. - Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists.
Ouyang Q, Tong Q, Feng R, Myint KZ, Yang P, Xie XQ. Ouyang Q, et al. ACS Med Chem Lett. 2013 Apr 11;4(4):387-392. doi: 10.1021/ml3004236. ACS Med Chem Lett. 2013. PMID: 24729834 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical